Bionovis
Thiago Mares Guia has extensive experience in the pharmaceutical and biotechnology industry. Thiago has worked at Bionovis since 2012, starting as a Medical and Scientific Manager and later progressing to become the Scientific & Business Executive Director and Executive Vice President. In these roles, they were responsible for business development, alliance management, portfolio definition, clinical development planning, and leading various departments such as Quality Assurance and Regulatory Affairs. Prior to Bionovis, Thiago founded CellProtect Biotechnology, a company specializing in cell therapy for chronic degenerative diseases. Thiago also held research and leadership positions at the Cell and Molecular Therapy Center - NUCEL and worked as a consultant in the biotechnology and pharmaceutical industry. Thiago has a strong background in medical and scientific research, holding professor positions at different universities and participating in various forums and programs related to clinical research and health innovation.
Thiago Mares Guia has a diverse education history. Thiago first pursued a Doctor of Medicine (M.D.) degree in Medicine at the Universidade Federal de Minas Gerais, which they completed from 1992 to 1998. Following this, they continued their academic journey at the same university from 1999 to 2006, obtaining a Doctor of Philosophy (Ph.D.) degree in Biochemistry and Immunology. Later, from 2006 to 2008, they completed a Postdoctoral Fellowship in Cell Therapy and Biotechnology at the USP - Universidade de São Paulo.
This person is not in any teams
This person is not in any offices
Bionovis
1 followers
Bionovis is a pharmaceutical biotechnology company with a mission to research, develop, manufacture and market high-quality complex biopharmaceuticals to improve the lives of patients. Set in a promising global biopharmaceutical environment, Bionovis innovates as a pioneer in the production of highly complex biological medicines in Brazil. With a reputable team, global partnerships with industry leaders and collaborations with leading national public institutions, we are establishing the complete technology for the production of a variety of monoclonal antibodies and therapeutic proteins. Highly qualified human resources, a world-class infrastructure and the implementation of state of the art know-how in the development and manufacturing of complex biological drugs are the pillars for the construction of a pipeline composed of biosimilars, biobetters and innovative biopharmaceuticals.